XBiotech (XBIT) shares were down over 25% Monday after the company said it is pausing its rheumatology clinical program due to irregularities in the phase II study of its candidate drug Natrunix for rheumatoid arthritis.
The study, which included about 230 participants with moderate to severe rheumatoid arthritis, did not achieve its primary endpoint of an American College of Rheumatology response rate after 12 weeks, the company said.
XBiotech said it found irregularities at the top enrolling clinical sites, including multiple enrollments of the same subjects, which raised concerns about data validity. As a result, the company has paused further planned studies in arthritis and ankylosing spondylitis while it evaluates the findings.
Price: 4.78, Change: -1.60, Percent Change: -25.08
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。